Avantor announces strategic partnership with BlueWhale Bio

Avantor (AVTR) announced a strategic partnership with BlueWhale Bio, a commercial-stage company dedicated to immune cell therapy manufacturing and addressing CAR-T production by streamlining manufacturing, reducing variability, and shortening time-to-patient. The partnership combines Avantor’s bioprocessing and custom ancillary-reagent manufacturing capabilities with BlueWhale Bio’s Synecta cell-derived nanoparticle platform, which mimics natural T-cell stimulation. The collaboration aims to accelerate CDNP manufacturing scale-up to help CAR-T developers significantly reduce expansion time – potentially expanding patient access and manufacturing capacity across the growing cell therapy sector.